CerebraAI HEATMAP Module
Advanced visualization of brain tissue pathology (e.g., ischemia)
Development / PilotLaunched 2022, enhanced 2023. In clinical pilot/validation.
Key Facts
Indication
Advanced visualization of brain tissue pathology (e.g., ischemia)
Phase
Development / Pilot
Status
Launched 2022, enhanced 2023. In clinical pilot/validation.
Company
About Cerebra AI
Cerebra AI's mission is to create AI solutions that are essential, not just 'nice to have,' in emergency medicine, aiming to improve outcomes when every second counts. Founded from an AI lab in Kazakhstan, the company has achieved significant milestones including regulatory approval in Kazakhstan, deployment in over 50 hospitals, and a growing proprietary dataset of over 150,000 patients. With a strategic relocation to the U.S. and a pending FDA submission, Cerebra AI is positioning itself to become a key player in the global AI-powered neuroimaging diagnostics market.
View full company profile